Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)
Year: 2017
Type: article
Source: Annals of Oncology
Institutions: Mayo Clinic, Ospedale Policlinico San Martino, Dana-Farber Cancer Institute, National Cancer Center Hospital East, Cancer Research UK, University of Glasgow, Sorbonne Paris Cité, Hôpital Européen Georges-Pompidou, Université Paris Descartes, University Hospital of Heraklion, Churchill Hospital, University of Oxford, Ospedale Papa Giovanni XXIII, The Barbara Ann Karmanos Cancer Institute, Inserm, Centre Hospitalier Universitaire de Besançon, Methodology and Quality of Life Unit in Oncology, Yokohama City University, Duke University, Mario Negri Institute for Pharmacological Research, Hôpital Saint-Antoine, University Hospital Southampton NHS Foundation Trust
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2761055239